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Abstract
Aims: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures
(PROMs) could replace clinical and/or photographic assessments. Data from the Standardisation of Breast Radiotherapy (START) trials are examined.
Materials and methods: NTEs in the treated breast were recorded by (i) annual clinical assessments, (ii) photographs at 2 and 5 years, (iii) PROMs at 6 months, 1,
2 and 5 years after radiotherapy. Hazard ratios for the radiotherapy schedules were compared. Measures of agreement of assessments at 2 and 5 years tested
concordance.
Results: PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had clinical and 1444 had photographic assessments. All methods were
sensitive to the dose difference between schedules. Patients reported a higher prevalence for all NTE end points than clinicians or photographs (P < 0.001 for
most NTEs). Concordance was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 0.21 (shrinkage and oedema). The percentage
agreement was lowest between PROMs and photographic assessments of change in breast appearance (38%).
Conclusions: All three methods produced similar conclusions for the comparison of trial schedules, despite low concordance between the methods on an
individual patient basis. Careful consideration should be given to the different contributions of the measures of NTE in future radiotherapy trials.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Traditional outcome measures of normal tissue re-
sponses to radiotherapy rely heavily, often exclusively, on
clinical assessments using graded scales to score a wide
range of early and late adverse effects [1e4]. Scoring sys-
tems, including Late Effects in Normal Tissues Subjective,
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1 Joint last authors.
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creativecommons.org/licenses/by-nc-nd/4.0/).Radiation Therapy Oncology Group (RTOG) and Common
Terminology Criteria for Adverse Events (CTCAE), feature
symptomatology requiring health professionals to elicit and
score responses to direct questions. Photographic assess-
ments of a change in breast appearance from a pre-
radiotherapy baseline have become increasingly used in
randomised trials of radiotherapy as they are usually scored
by a small number of observers blind to patient identity,
treatment allocation and year of follow-up, unlike the
clinical assessments, which are scored by a large number of
individuals in a multicentre study [5]. In parallel, the use of
carefully developed and validated quality of life in-
struments in psychosocial research and phase III cancer
clinical trials has expanded considerably [6e8], togetherd. This is an open access article under the CC BY-NC-ND license (http://
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outcome measures (PROMS) in routine follow-up [9].
With an increasing use of PROMs in cancer clinical trials
[10,11], it is worth asking howcomparable and interpretable
are the different methods of assessment, and whether
PROMs could become the primary means of scoring late
normal tissue effects (NTE) of breast radiotherapy in trials.
Against this background, the large-scale UK Standardisation
of Breast Radiotherapy (START) randomised trials [12e15]
of hypofractionated radiotherapy after primary surgery for
early breast cancer were used to conduct exploratory ana-
lyses comparing different methods of assessment of late
NTE after adjuvant breast radiotherapy with the primary
aim of assessing if PROMs might take priority over, or
replace, clinical and/or photographic assessments as
outcome measures.Materials and Methods
The START-A and START-B trials recruited 4451 women
between 1998 and 2002 from 35 UK radiotherapy centres
(ISRCTN59368779, MREC(1)98/86). Centres could opt to
participate in the PROMs and photographic assessment
studies, and if they participated, they were expected to
invite every eligible trial patient to join. Thirty-one (89%)
centres opted to participate in the PROMs study and 29
(83%) in a photographic assessment study of the change in
breast appearance. Women with operable invasive breast
cancer (International Union Against Cancer pT1-3a pN0-
1 M0) requiring radiotherapy after surgery (breast-
conserving surgery or mastectomy, with clear tumour
margins 1 mm) were eligible for the trials if they were
aged over 18 years, did not have an immediate surgical
reconstruction and were available for follow-up. Trial A
patients were randomised to either 50 Gy in 25 fractions
(control) or 41.6 Gy in 13 fractions of 3.2 Gy or 39.0 Gy in 13
fractions of 3.0 Gy over 5 weeks. Trial B patients were
randomised to either 50 Gy in 25 fractions over 5 weeks
(control) or 40 Gy in 15 fractions of 2.7 Gy over 3 weeks. Full
details of the recruitment, and radiotherapy planning, de-
livery and veriﬁcation protocols have been previously re-
ported, as has the PROMs study [12e14].
Patients in the PROMs study completed baseline mea-
sures in clinic and were sent questionnaires to complete at
home at 6 months, 1, 2 and 5 years after radiotherapy.
Clinical assessments of NTEwere collected at annual follow-
up in all patients, and photographs were taken under
standard conditions at a post-surgical pre-radiotherapy
baseline and at 2 and 5 years after randomisation for pa-
tients who had breast-conserving surgery. The patient
questionnaires included the (i) European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30 core
questionnaire and QLQ-BR23 breast-speciﬁc module [6,16],
from which the assessment of breast swelling over the
previous 4 weeks (not at all, a little, quite a bit, very much)
was used in this study of concordance, (ii) Hospital Anxiety
and Depression Scale [17], (iii) 10-item Body Image Scale
[18] and (iv) four protocol-speciﬁc questions asking patientsto score ‘change in breast appearance’, ‘breast hardness/
ﬁrmness’, ‘reduction in size of breast’ and ‘change in skin
appearance’ since radiotherapy; the ﬁrst three questions
applying only to patients with conserved breasts, and all
items scored on a four-point scale (none, a little, quite a bit,
very much).
The annual clinical assessments of breast shrinkage,
breast induration, telangiectasia and breast oedema were
scored using the contralateral breast as a comparator and
four-point graded scales (none, a little, quite a bit, very
much). Change in photographic breast appearance since
radiotherapy was scored by a single team of three observers
blind to patient identity, trial treatment allocation, year of
follow-up and radiotherapy centre. The scoring method was
validated in the START pilot trial [5]. Photographs at 2 and 5
years after radiotherapy were compared with a pre-
radiotherapy (post-surgery) baseline and an overall score
allocated for change in photographic breast appearance in
the treated breast based on change in size, shrinkage and
shape, on a three-point scale (no change, mild change,
marked change). Post-mastectomy patients were included
in the PROMs and clinical assessments but not in the
photographic assessments. Individual NTE were mapped
between the different assessment methods in order to
compare corresponding outcomes, as shown in Table 1.
Statistical Methods
NTE assessments at all time points in the trials were
included in the comparison of radiotherapy schedules (i.e.
from 6 months to 5 years for the PROMs, from 1 to 5 years
for the clinical assessments, and at 2 and 5 years for the
photographs). Time to ﬁrst NTE event [deﬁned as ‘quite a
bit’ or ‘very much’ for the PROMs and clinical assessments,
and any change (mild or marked) in photographic breast
appearance] was calculated from the date of randomisation,
and survival analysis methods used to compare radio-
therapy schedules. Hazard ratios for the relative effects of
the radiotherapy schedules in START-A were calculated for
each NTE end point using Cox proportional hazards
regression and compared between the different assessment
methods using forest plots. Estimates of the a/b ratio for
NTEs, which describes the sensitivity of normal tissues to
fraction size, were obtained separately for the PROMs,
clinician and photographic end points in START-A. Esti-
mates of relative effects of the fractionation schedules in
START-B are not presented in this paper as they do not
contribute to the measurement of fraction sensitivity, only
having two randomised groups in Trial B. Hazard ratios for
the fractionation schedules in START-B have been published
separately for the different NTE assessments, and showed
consistent results [13e15].
For the concordance analyses, data from START Trials A
and B were combined, and only 2 and 5 year assessments
included as these were the time points at which all three
NTE assessment methods were used in the trials. For all
PROMs and clinically assessed end points there were few
patients in the highest grade category, so moderate and
marked categories were combined, resulting in three-point
Table 1
Clinical and photographic outcome measures of speciﬁc late normal tissue effects in the breast and the corresponding patient-reported
outcome measure (PROM)
Clinical assessment of late normal tissue effect in the
treated breast
Corresponding PROM used to test concordance with clinical or
photographic assessmentz
Has the patient had any of the following adverse effects?
Compare with contralateral breast*:
Breast shrinkage Has your affected breast become smaller as a result of your
radiotherapy?x
Breast induration Has your affected breast become harder/ﬁrmer to the touch since
your radiotherapy?x
Breast oedema During the past 4 weeks, was the area of your affected breast
swollen?{
Telangiectasia Has the appearance of the skin in the area of your affected breast
changed since your radiotherapy?x
Has there been a change in photographic breast appearance
compared with pre-radiotherapy baseline photograph?y
Has the overall appearance of your affected breast changed,
compared with the other side, as a result of your radiotherapy?x
* Clinical assessments scored as none, a little, quite a bit, very much.
y Photographic assessments scored as no change, mild change, marked change.
z PROMs scored as not at all, a little, quite a bit, very much.
x Protocol-speciﬁed items included in the patient questionnaire booklet under the heading ‘Since your breast radiotherapy’.
{ Question from the EORTC QLQ-BR23 breast cancer module.
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very much (‘moderate/marked’); this also enabled com-
parison with the photographic assessments, which were
scored on a similar three-point scale. Corresponding NTE
end points were matched between the PROMs, clinical and
photographic assessments at each time point and compared
on an individual patient basis using measures of concor-
dance, including percentage agreement (with 95% conﬁ-
dence interval), weighted kappa statistic (with 95%
conﬁdence interval) and Bowker’s test of symmetry [19].
Guidelines for interpreting the value of the weighted kappa
statistic in terms of the strength of agreement are <0.20:
poor; 0.21e0.40: fair; 0.41e0.6: moderate; 0.61e0.8: good;
0.81e1.00: very good [20]. Bowker’s test assesses the sym-
metry of a square table, i.e. whether there are more obser-
vations on one side of the diagonal than the other. The
concordance analyses were also carried out stratifying on
baseline patient characteristics such as age and quality of
life scores (including anxiety and depression from the
Hospital Anxiety and Depression Scale and body image
from the Body Image Scale), to investigate whether these
had any effect on the degree of concordance between NTE
assessment methods.Results
Of the 2208 women recruited into the overall START
Trials PROMs study, self-assessments of NTEs were available
at 2 and/or 5 years for 1939 (88%) patients, of whom 1870
also had clinical assessments at the same time points (85%
of all patients in the PROMs study). Patient characteristics at
baseline for the 1870 patients in this analysis are shown in
Table 2, of whom 1574/1870 (84.2%) had breast-conserving
surgery and 1444/1574 (91%) had photographic assessments
at 2 and/or 5 years.Treatment effects on late NTE assessed by PROMs and by
annual clinical assessment in START-A are shown side-by-
side in Figure 1. Two test schedules (41.6 Gy and 39 Gy in
13 fractions) were compared with the control (50 Gy in 25
fractions) in START-A. Comparing hazard ratios for corre-
sponding end points, it can be seen that the treatment ef-
fects were of a similar size for PROMs and clinical
assessments, with overlapping conﬁdence intervals. Treat-
ment effects on late NTE assessed by PROMs and by pho-
tographs for overall change in breast appearance were also
similar (Figure 2). a/b estimates (adjusted for prognostic
factors) for overall change in breast appearance were 2.9 Gy
(95% conﬁdence interval 0.7e5.1 Gy) for PROMs and 2.6 Gy
(95% conﬁdence interval 1.3e3.9 Gy) for photographic as-
sessments. a/b estimates for individual NTE end points from
clinical assessments have been reported [14] (there was no
clinical assessment of overall cosmesis in the START Trials).
The comparison of overall rates of NTEs reported by
PROMs and clinical assessments from START Trials A and B
combined showed that patients reported a higher preva-
lence of breast changes (Figure 3aed). Concordance be-
tween the assessments of corresponding NTEs on an
individual patient basis was generally poor (Table 3). The
lowest levels of percentage agreement between PROMs and
clinicians were observed for breast induration/hardness
(47% and 50% at 2 and 5 years, respectively) and breast
shrinkage (53% and 47% at 2 and 5 years). The highest level
of percentage agreement between PROMs and clinicians
was for breast swelling/oedema (78% and 86% at 2 and 5
years), but the overall prevalence of oedema was very low
(Figure 3c). Weighted kappa statistics also highlighted the
low agreement between methods, ranging from 0.05 for
telangiectasia at 2 years (indicating poor agreement) to 0.21
for each of breast shrinkage and breast oedema at 2 years
(indicating fair agreement). Results of Bowker’s test of
symmetry were highly statistically signiﬁcant for all NTE
Table 2
Baseline characteristics of 1870 Standardisation of Breast Radio-
therapy (START) Trial A and B patients with patient-reported
outcome measures (PROMs) and clinical assessments of normal
tissue effects at 2 and/or 5 years after radiotherapy
Number of
patients (%)
Age (years): mean (standard deviation)
[range]
57.0 (10.0)
[27.1e86.0]
Type of primary surgery
Breast-conserving surgery 1574 (84.2)
Mastectomy 296 (15.8)
Axillary surgery
None 55 (2.9)
Axillary clearance 1284 (68.7)
Axillary sampling 495 (26.5)
Sentinel node biopsy 36 (1.9)
Adjuvant chemotherapy
No 1268 (67.8)
Yes 598 (32.0)
Unknown 4 (0.2)
Tamoxifen
No 312 (16.7)
Yes 1554 (83.1)
Unknown 4 (0.2)
Breast size*
Small 154 (8.2)
Medium 1126 (60.2)
Large 228 (12.2)
Unknown e not in photographic study 362 (19.4)
Surgical deﬁcit
Small 872 (46.6)
Medium 496 (26.5)
Large 140 (7.5)
Unknown e not in photographic study 362 (19.4)
Hospital Anxiety and Depression Scaley
Anxiety
Normal (0e7) 1287 (68.8)
Borderline (8e10) 322 (17.2)
Case (11þ) 256 (13.7)
Unknown 5 (0.3)
Depression
Normal (0e7) 1658 (88.7)
Borderline (8e10) 152 (8.1)
Case (11þ) 52 (2.8)
Unknown 8 (0.4)
Body Image Scalez (10-items): median
(interquartile range) [range]
3 (0e8) [0e30]
* Breast size and surgical deﬁcit assessed from baseline
photographs.
y Hospital Anxiety and Depression Scale ranges from 0 to 21.
z Body Image Scale ranges from 0 to 30, where a higher score
indicates more concerns; unknown for 79 patients.
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scoring between the different methods, with patients
reporting more breast changes compared with clinical and
photographic assessments (Table 3). There seemed to be no
substantial differences in degree of concordance for indi-
vidual NTE end points according to time since radiotherapy,
i.e. between 2 and 5 years (Table 3).The comparison of PROMs and photographic assess-
ments showed that patients reported a higher prevalence of
overall change in breast appearance since radiotherapy and
graded effects as more severe compared with the photo-
graphic assessments (Figure 3e). In testing concordance,
agreement on an individual patient basis was low at 2 and 5
years (38% for each), with lowweighted kappa values (0.09)
and highly statistically signiﬁcant discordance (P < 0.001
for Bowker’s test of symmetry); Table 3. Concordance of
PROMs with clinical and photographic assessments of NTE
seem to be unaffected by patient factors, including age,
breast size, surgical deﬁcit, baseline Hospital Anxiety and
Depression Scale anxiety and depression and body image
scores (see table in web appendix).Discussion
Concordance between PROMs and NTE assessments as
scored by clinicians and from photographs on an individual
patient basis was poor. The percentage agreement between
PROMs and clinical assessments of speciﬁc NTEs was
around 50%, indicating that in only half the patients the NTE
was graded in the same category of severity corresponding
to none, mild, moderate/marked. Agreement was even
lower between PROMs and photographs, where less than
40% graded NTEs the same. In our study, patients scored
NTEs more frequently and more severely than results from
clinicians or photographs. Concordance did not seem to be
affected by patient characteristics, including psychological
measures (anxiety and depression), body image and factors
associated with risk of NTEs (age, breast size and surgical
deﬁcit). It may not be surprising that concordance between
the assessment methods on an individual patient basis was
poor; this has been consistently reported in other studies
[21e24]. These differences in ratings reﬂect the different
paradigms in which symptoms are perceived and rated;
these include variance in context, values, expectations and
methodological inﬂuences, as well as the different socio-
cultural backgrounds of subjects and doctors [25]. Pub-
lished comparisons of clinician and patient self-
assessments show considerable variability between rat-
ings, especially for more subjective symptoms and often
report, as in our study, a relative underestimate by clinicians
compared with patients (e.g. [23,24,26e30]). However, the
concordance analysis of NTE assessments in the Cambridge
intensity-modulated breast radiotherapy trial found the
opposite, with clinicians and photographic assessments
reporting more NTEs compared with patients, possibly
because the study was carried out in a single centre, with
clinical ratings carried out by one person [31]. Others have
shown a more favourable rating of overall cosmesis after
conservative treatment for breast cancer by patients
compared with clinicians [32,33], although these ﬁndings
are not necessarily speciﬁc to late effects of radiotherapy.
Kirchheiner et al. [34] argued that some variation is ‘quite
acceptable and comprehensible’, given the methodological
differences between morbidity scoring by clinicians and
patient-reported symptoms. Clinical and patient symptom
Fig 1. Comparisons between randomised radiotherapy schedules in Standardisation of Breast Radiotherapy (START) Trial A for patient-reported
outcome measures (PROMs) and clinical assessments of speciﬁc normal tissue effects.
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given that they often have different values and purposes,
with patient assessments inherently encompassing impact
on quality of life.
However, our study showed that despite the discordance
between assessments on an individual basis, the three
methods (PROMs, clinical and photographs) generated
similar estimates of relative treatment effects on NTEwithin
the trials [12,14,15]. The discriminatory power of different
assessments was equally good, in that PROMs generated the
same estimates of a/b value for NTE in START-A (around
3 Gy) as photographs and clinical assessments (data for a/b
values of clinical assessments of NTEs previously published
[14]). From the trial outcome perspective, this consistency
of treatment effects adds considerable weight to the overall
interpretation and conclusions of the trial. However, the
PROMs reported here were selected from a large number of
multidimensional items assessed as part of the START
quality of life sub-study, most of which would not beFig 2. Comparisons between randomised radiotherapy schedules in
Standardisation of Breast Radiotherapy (START) Trial A for patient-
reported outcome measures (PROMs) and photographic assess-
ments of overall change in breast appearance.expected to discriminate so clearly between the schedules
in the START trials, but are of value in understanding the
experience of treatment effects over time. The PROMs items
included in this analysis of concordance were those directly
relevant to the hypothesis under test in the clinical trial and
therefore probably sensitive to randomised differences in
radiotherapy dose intensity. The PROMs needed to have a
recognisable relationship with the pathophysiology (atro-
phy, ﬁbrosis) of NTE, broadly corresponding to clinical
scoring of change in size (atrophy), shape and texture
(oedema, ﬁbrosis) of the breast and change in photographic
breast appearance (atrophy, distortion/ﬁbrosis). This is in
contrast with other clinically relevant domains, such as
physical and social functioning, that explore the effect on
different aspects of quality of life [6,16].
Clinicians are taught in training that symptomatology is
the key to diagnosis, which they can only judge by listening
to their patients and framing relevant questions. Clinicians
act as surrogates for their patients in this context, so that if
the relevant questions are known in advance (as they are in
a clinical trial), there seems to be a good reason to prioritise
the PROMs over the physical clinical assessments. Where
physical signs are concerned, including breast size, shape
and texture, this study suggests that patients are as sensi-
tive as their doctors in scoring these changes too, provided
the questions are framed appropriately. In this respect, it is
possible to criticise our PROMs question, which asked pa-
tients to score changes since radiotherapy to the affected
breast compared with the clinical assessment that
compared the treated with the untreated breast at the time
of the annual examination. Despite a variety of factors ex-
pected to inﬂuence howawoman responds to this question,
the sensitivity to randomised dose indicates that the
radiotherapy ‘signal’ was not lost. Doctors also develop their
own frames of reference when assessing NTE, and the
hundreds of clinical observers involved in scoring NTE in
Fig 3. Comparison of 5 year patient-reported outcome measures (PROMs), clinical and photographic assessments of speciﬁc normal tissue
effects in Standardisation of Breast Radiotherapy (START) Trials A and B.
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trials, necessarily contribute a lot of ‘noise’ in a scoring
system. However, a disadvantage of reliance on PROMs in
clinical trials is that they are traditionally labour-intensive
to administer and generate large volumes of data, making
heavy demands on trial management and statistical re-
sources. Since modern data capture systems are increas-
ingly able to collect outcome data directly from the patient
(e.g. via an App), dispensing with clinical follow-up may
appeal to patients as well as health services operating under
increasing pressures [35]. However, radiation effects are not
viewed in isolation by patients and attention also needs tobe paid to their concerns in the context of multimodal
treatments and adverse effects over time. Up to a third of
patients report moderate or marked symptoms of the
breast, arm and shoulder at 5 years, which may warrant
engagement and advice from their clinical teams [13]. Thus,
more preparation and after care is needed for the success of
patient self-management post-treatment and to improve
quality of life [36]. Furthermore, the acceptability of elec-
tronic symptom reporting warrants evaluation in an aging
population.
Despite adding to the administrative burden of clinical
trials, the photographic assessments of NTEs provide
Table 3
Concordance between patient-reported outcome measures (PROMs) and clinical or photographic assessments of speciﬁc normal tissue
effects at 2 and 5 years in Standardisation of Breast Radiotherapy (START) Trials A and B
Clinicians Patients % agreement (95%
conﬁdence interval)
Weighted kappa (95%
conﬁdence interval)
Bowker’s test of
symmetry, P-valueNone A
little
Quite a bit /very much
Breast shrinkage* e 2 years 755/1413;
53.4%
(50.8e56.1%)
0.21
(0.17e0.25)
<0.001
None 566 335 83
A little 107 158 70
Quite a bit/very much 18 45 31
Breast shrinkage* e 5 years 579/1221; 47.4%
(44.6e50.3%)
0.19
(0.15e0.24)
<0.001
None 372 277 126
A little 96 151 87
Quite a bit/very much 18 38 56
Breast induration/hardness* e 2 years 676/1439
47.0%
(44.4e49.6%)
0.12
(0.08e0.16)
<0.001
None 493 379 136
A little 112 152 73
Quite a bit/very much 31 32 31
Breast induration/hardness* e 5 years 610/1222; 49.9%
(47.1e52.8%)
0.12
(0.07e0.16)
<0.001
None 482 295 94
A little 121 105 40
Quite a bit/very much 22 40 23
Breast oedema/swelling* e 2 years 1144/1465; 78.1%
(75.9e80.2%)
0.21
(0.15e0.26)
0.017
None 1092 146 21
A little 109 51 9
Quite a bit/very much 16 20 1
Breast oedema/swelling* e 5 years 1089/1260; 86.4%
(84.4e88.2%)
0.10
(0.04e0.17)
0.003
None 1076 86 19
A little 54 13 3
Quite a bit/very much 6 3 0
Telangiectasia/change in skin appearancey e 2 years 959/1721;
55.7%
(53.3e58.1%)
0.05
(0.02e0.07)
<0.001
None 911 572 134
A little 32 42 11
Quite a bit/very much 6 7 6
Telangiectasia/change in skin appearancey e 5 years 900/1446; 62.2%
(59.7e64.7%)
0.08
(0.04e0.12)
<0.001
None 859 369 90
A little 47 30 16
Quite a bit/very much 13 11 11
Photographs
Overall change in breast appearance* e 2 years 489/1290;
37.9%
(35.3e40.6%)
0.09
(0.06e0.11)
<0.001
None 331 525 130
Mild 56 141 78
Marked 4 8 17
Overall change in breast appearance* e 5 years 409/1064; 38.4%
(35.5e41.4%)
0.09
(0.06e0.12)
<0.001
None 258 344 123
Mild 66 140 108
Marked 5 9 11
* Breast-conserving surgery patients only.
y Breast-conserving surgery and mastectomy patients.
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generally by the same small team of observers who are
blind to patient identity, randomised treatment allocation,
year of follow-up and participating hospital. As it is gener-
ally not possible to blind treatment allocation in radio-
therapy trials, the photographic assessments provide the
only unbiased comparison of NTEs between randomised
groups. In addition, as photographs provide a permanent
record of breast effects at a ﬁxed point in time, the assess-
ments can be validated by repeat scoring from different
teams of observers [5], thus making the scoring morestandardised than PROMs or clinical assessments from
physical examination. Photographs can also be ﬁled and
stored for use in future translational research investigating
adverse effects of radiotherapy. There are some disadvan-
tages to the use of photographic assessments in clinical
trials, including ﬁnancial and staff resources required, and
they can be disliked by patients, but these are outweighed
by the beneﬁts of retaining an unbiased comparison of NTEs
within radiotherapy trials.
There is growing interest in investigating inherited risk
factors for radiotherapy NTE, for which robust measures of
J.S. Haviland et al. / Clinical Oncology 28 (2016) 345e353352NTE are needed that have a close relationship to the un-
derlying pathophysiology [37]. In this respect, the lack of
concordance reported in this study is intriguing and
potentially worrying. The prevalence and severity of NTEs
reported by patients, clinicians and from photographs
during follow-up were widely discordant in most cases. In
trying to identify subgroups of patients with levels of NTE
that are much more, or much less, severe than expected on
the basis of known factors (breast size, radiotherapy dose
etc.), it is not possible to judge whether the clinical and
photographic assessments of NTE severity are more or less
valid than the PROMs, hence making identiﬁcation of po-
tential cases (and controls) for translational studies very
difﬁcult. Perhaps much depends on how the NTE assess-
ment questions to patients and clinicians are posed,
something that this study does not address.
In conclusion, the PROMs, clinical and photographic as-
sessments of late NTE in the START trials generated
consistent estimates of relative treatment effects between
randomised groups, adding weight to the trials’ overall
ﬁndings. Discordance in the prevalence rates of NTE re-
ported by the patients, clinicians and photographs could be
expected for a number of well-established reasons, but this
does not undermine an argument for prioritising PROMs
and photographic assessments of NTEs in breast radio-
therapy trials.
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